Ann: Becoming a substantial holder, page-17

Good question Patrick been looking for something some business analyst may have written pros and cons in regard Mayne Mithra contractual agreement , assumed this contract would have been well scrutinised analytically before and after FDA approval maybe there were negative reports and didn't see them . Mithra accepting payment (for licence agreement) mostly in shares seemed to suggest to me anyway a degree of confidence in Mayne sustainability and capabilities to market their product successfully . No buying support by directors /insiders market generally and E4 selling beginning July shares around .36 .Guessing market doesn't trust management with their money or getting something right for change , probably both .